
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed is well positioned because BRINSUPRI has converted a long-ignored market into a real commercial franchise, becoming the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis and already surpassing $1B in revenue within its first four full quarters. Strong 3Q26 results reinforced that thesis, with total revenue of $524.4M, BRINSUPRI revenue of $400.1M, ARIKAYCE revenue of $124.4M, and raised 2026 guidance of $1.35B-$1.4B for BRINSUPRI and $460M-$470M for ARIKAYCE. Beyond the launch, the company has multiple additional value drivers in a >$6B TPIP program, expanded ARIKAYCE opportunity, and a large U.S. bronchiectasis population of roughly 500K-550K diagnosed patients, supporting a positive long-term outlook.
Bears say
Insmed is facing a weaker fundamental setup because the stock depends heavily on Brinsupri commercialization, yet the company has not disclosed persistence data and new patient starts may slow below the guided ~7,000 per quarter as the initial backlog is absorbed. Arikayce adds risk despite a 2026 estimate of $467M and U.S. list price of $220,012 per patient-year, because slower frontline adoption, softer refractory demand, and guideline timing uncertainty could limit the modeled 17% lower peak to $1.5B in 2034. The outlook is further pressured by a heavier cost structure, with 2027 R&D of $1,022M and SG&A of $1,133M, multiple concurrent TPIP Phase 3 launches, and a 2027 EPS estimate cut to $1.24 from $3.26.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Insmed (INSM) Forecast
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares